This content was published in the EU4MD update released on 15.12.2021. This update also presents a section on partnerships, announcements, studies, upcoming events, and a research corner.
EU4MD project advisory committee takes stock of results and outlines next steps
The EU4Monitoring Drugs (EU4MD) project advisory committee held its third meeting on 30 November to take stock of results achieved to date and outline its next steps. The online meeting brought together over 40 participants. The meeting reviewed preliminary results of ongoing work as well as perspectives for the coming months.
The EMCDDA’s EU4MD project is extended by six months to the end of 2022. The project was launched in January 2019 for an initial period of three years, and was first extended to June 2022. The latest decision to extend the project further was taken by the European Commission’s Directorate-General for Neighbourhood and Enlargement Negotiations (DG NEAR) on account of significant delays to its activities triggered by the COVID-19 restrictions. By the end of 2022, it is expected that these delayed milestones will have been met.
